Fingolimod significantly reduced brain volume loss in patients with relapsing-remitting multiple sclerosis: 4-year data from FREEDOMS extension study

被引：0
|
作者：
Radue, E.
Kappos, L.
O'Connor, P.
Polman, C.
Hohlfeld, R.
Calabresi, P.
Selmaj, K.
de Vera, A.
Sfikas, N.
Zhang-Auberson, L.
Francis, G.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[4] Univ Munich, Munich, Germany
[5] Johns Hopkins Multiple Sclerosis Ctr, Baltimore, MD USA
[6] Med Acad Lodz, Lodz, Poland
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [41] Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study
    Baldi, Eleonora
    Guareschi, Angelica
    Vitetta, Francesca
    Senesi, Caterina
    Curti, Erica
    Montepietra, Sara
    Simone, Anna Maria
    Immovilli, Paolo
    Caniatti, Luisa
    Tola, Maria Rosaria
    Pesci, Ilaria
    Montanari, Enrico
    Sola, Patrizia
    Granella, Franco
    Motti, Luisa
    Ferraro, Diana
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (09) : 1849 - 1855
  • [42] Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 years in Patients with Relapsing-Remitting Multiple Sclerosis
    Hohlfeld, Reinhard
    Kappos, Ludwig
    Tomic, Davorka
    Silva, Diego
    Ringwald, Kathrin
    Meier, Daniela Piani
    Selmaj, Krzysztof
    NEUROLOGY, 2017, 88
  • [43] Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 Years in Patients with Relapsing-Remitting Multiple Sclerosis
    Hohlfeld, Reinhard
    Kappos, Ludwig
    Tomic, Davorka
    Silva, Diego
    Ringwald, Kathrin
    Meier, Daniela Piani
    Bakshi, Rajesh
    Selmaj, Krzysztof
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 394 - 394
  • [44] Effect of oral fingolimod treatment on brain volume loss in patients with relapsing- remitting multiple sclerosis estimated using Bayesian methodology
    Yin, Guosheng
    Meng, Xiangyi
    Islam, M. Zahur
    NEUROLOGY, 2017, 88
  • [45] Inclusion of brain volume loss in a revised measure of "no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
    Kappos, Ludwig
    De Stefano, Nicola
    Freedman, Mark S.
    Cree, Bruce A. C.
    Radue, Ernst-Wilhelm
    Sprenger, Till
    Sormani, Maria Pia
    Smith, Terence
    Haring, Dieter A.
    Meier, Daniela Piani
    Tomic, Davorka
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1297 - 1305
  • [46] REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
    Batista, S.
    Nunes, C. C.
    Cerqueira, J. J.
    Martins Silva, Ana
    Correia de Sa, J.
    Ferreira, J.
    Mendonca, M. T.
    Pinheiro, J.
    Salgado, V.
    Correia, A. S.
    Sequeira, J.
    Costa, A.
    Sousa, L.
    NEUROLOGICAL SCIENCES, 2021, 42 (05) : 1995 - 2003
  • [47] Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
    Barrero, Francisco
    Mallada-Frechin, Javier
    Luisa Martinez-Gines, Maria
    Eugenia Marzo, Maria
    Meca-Lallana, Virginia
    Izquierdo, Guillermo
    Ramon Ara, Jose
    Oreja-Guevare, Celia
    Meca-Lallana, Jose
    Forero, Lucia
    Sanchez-Veram, Irene
    Jose Moreno, Maria
    PLOS ONE, 2020, 15 (04):
  • [48] REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
    S. Batista
    C. C. Nunes
    J. J. Cerqueira
    Ana Martins Silva
    J. Correia de Sá
    J. Ferreira
    M. T. Mendonça
    J. Pinheiro
    V. Salgado
    A. S. Correia
    J. Sequeira
    A. Costa
    L. Sousa
    Neurological Sciences, 2021, 42 : 1995 - 2003
  • [49] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
    Sharmin, S.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Skibina, O.
    Buzzard, K.
    van der Walt, A.
    Vucic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 8 - 9
  • [50] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
    Sharmin, S.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Skibina, O.
    Buzzard, K.
    van der Walt, A.
    Vucic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 8 - 9
12345